SITE011-0367

completed

Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE011 (ITA) (Dr. Jansen) · consented 2023-05-03

Adverse events

Serious AEs

Open data queries

Luna dropout signal

–

Adverse events

severe assessed 2026-08-18

Grade 3 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-08-04 (study day 79); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-03-30 (study day 318); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2024-04-24 (study day 343); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-07-02 (study day 412); relationship: Y

mild assessed 2026-08-18

Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2024-10-23 (study day 525); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2025-01-03 (study day 597); relationship: not assessed

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.